×

Should AbbVie still pursue Shire?

2:15 AM ET Wed, 15 Oct 2014

Cole Smead, portfolio manager at Smead Capital Management, says that AbbVie's acquisition of Shire would be "very accretive" to shareholders and that the tax inversion part is not that important.